BioXcel Therapeutics, Inc. Research And Development Expense

• BioXcel Therapeutics, Inc. showed a decrease of -0.6% in Research And Development Expense from 2024 to 2025.
• This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), BioXcel Therapeutics, Inc.'s Research And Development Expense has grown by 1,024.6%.
• Historical annual values: Fiscal year 2025: $30.25 million | Fiscal year 2024: $30.44 million | Fiscal year 2023: $84.33 million | Fiscal year 2022: $91.24 million | Fiscal year 2021: $52.71 million | Fiscal year 2020: $58.00 million | Fiscal year 2019: $25.80 million | Fiscal year 2018: $14.56 million | Fiscal year 2017: $2.69 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026